Travere Therapeutics, Inc. stock is up 55.02% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45% of the previous 20 December’s closed higher than November. In the last 5 Unusual Options Trades, there were 4 PUTs, 1 CALL. 67% of analysts rate it a buy.
|Date & Time||Expiration Date||Strike Price||Trade Type||Size||Open Interest|
|16 Oct 16:08||20 Oct, 2023||10.00||563|
|15 Nov 18:45||21 Jun, 2024||7.50||3617|
|15 Nov 19:25||21 Jun, 2024||7.50||3617|
|01 Dec 20:56||21 Jun, 2024||7.50||5634|
|08 Dec 17:21||15 Mar, 2024||7.50||53|
Travere Therapeutics, Inc. focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the. treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy.